Form 4: Quest Diagnostics Executive Sam Samad Reports Acquisition of Common Stock

Executive Vice President & CFO of Quest Diagnostics, Sam Samad, reports acquiring 37 shares of common stock through a dividend reinvestment plan.

Summary

• Sam Samad, Executive Vice President & CFO of Quest Diagnostics, filed a Form 4.
• The filing reports the acquisition of 37 shares of Quest Diagnostics common stock on October 21, 2024, at a price of $149.371 per share.
• These shares were acquired through a dividend reinvestment plan.
• Following the transaction, Samad directly owns 17,504 shares of Quest Diagnostics common stock.
• The filing also mentions an award of restricted share units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating an executive's participation in a dividend reinvestment plan, which is neither particularly positive nor negative.

Positives

• The acquisition of shares through a dividend reinvestment plan demonstrates the executive's confidence in the company's future.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive sentiment and potential alignment of interests.

Stakeholder Impact

• The transaction provides stakeholders with insight into the executive's investment activity and alignment with shareholder interests.

Key Dates